Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining dose density and intensity as well as monitoring toxicity.
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib and trametinib; and neoadjuvant ipilimumab and nivolumab therapy.
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.
For more information about this ongoing trial, visit clinicaltrials.gov
ClinicalTrials.gov ID: NCT03132636
Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib and the mechanisms of resistance; and ALESIA, which examined crizotinib dosing.
Lisa A. Carey, MD, of the University of North Carolina, and Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, discuss the phase III IMpassion 130 trial testing the first-line combination of the PD-L1 inhibitor atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (Abstract LBA1_PR).
Sibylle Lobil, MD, PhD, of the German Breast Group, discusses findings in metastatic breast cancer from the IMpassion130 trial in triple-negative disease and from the PALOMA3 and SOLAR-1 trials in hormone receptor–positive, HER2-negative disease (Abstracts LBA1_PR, LBA2_PR, LBA3_PR).
